BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-02-08 06:00 |
SECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO'S BGBC020…
|
English | 129.2 KB | ||
| 2021-02-08 06:00 |
SECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO'S BGBC020…
|
English | 6.2 KB | ||
| 2021-01-29 06:00 |
BERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY …
|
English | 46.6 KB | ||
| 2021-01-29 06:00 |
BerGenBio presenterer oppdateringer fra den pågående fase-II bemcentinib kombin…
|
Norwegian | 47.3 KB | ||
| 2021-01-29 06:00 |
BERGENBIO PRESENTS UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY …
|
English | 7.3 KB | ||
| 2021-01-29 06:00 |
BerGenBio presenterer oppdateringer fra den pågående fase-II bemcentinib kombin…
|
Norwegian | 7.2 KB | ||
| 2021-01-28 15:43 |
BerGenBio ASA: Primary Insider notification
|
English | 673 bytes | ||
| 2021-01-27 06:00 |
BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2020 RESULTS
|
Norwegian | 30.8 KB | ||
| 2021-01-27 06:00 |
BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2020 RESULTS
|
English | 2.6 KB | ||
| 2021-01-13 07:19 |
BERGENBIO PRESENTERER OPPDATERINGER FRA DEN PÅGÅENDE FASE-II BEMCENTINIB KOMBIN…
|
Norwegian | 45.8 KB | ||
| 2021-01-13 07:19 |
BERGENBIO PRESENTERER OPPDATERINGER FRA DEN PÅGÅENDE FASE-II BEMCENTINIB KOMBIN…
|
Norwegian | 6.7 KB | ||
| 2021-01-13 06:30 |
BERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUD…
|
English | 51.0 KB | ||
| 2021-01-13 06:30 |
BERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUD…
|
English | 6.5 KB | ||
| 2021-01-12 06:00 |
BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES
|
English | 44.1 KB | ||
| 2021-01-12 06:00 |
BERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES
|
English | 5.0 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
